Literature DB >> 16887681

Identification of Propionibacterium acnes by polymerase chain reaction for amplification of 16S ribosomal RNA and lipase genes.

Masahiko Nakamura1, Ikuyo Kametani, Shuichi Higaki, Takayoshi Yamagishi.   

Abstract

Propionibacterium acnes belongs to the cutaneous flora and is present in sebaceous follicles. The fatty acids that are released from sebum triglycerides by the action of this bacterial lipase play an important role in the pathogenesis of acne vulgaris. P. acnes is also involved in postoperative disorders and opportunistic infections in immunosuppressed hosts. Recently, it has been proposed that P. acnes causes sarcoidosis. Therefore, rapid isolation and identification of P. acnes is important. This study evaluated the polymerase chain reaction (PCR) for the detection of the 16S rRNA and lipase genes of P. acnes. The PCR used to detect the 16S rRNA gene could amplify the gene of P. acnes, but not the genes of the other tested strains of P. avidum, P. granulosum, P. lymphophilum, P. jensenii, P. acidipropionici and P. thoenii. The PCR to detect the lipase gene of P. acnes, however, could amplify not only the gene of P. acnes but also that of P. avidum. The PCR product of this lipase gene was not found in the strains of the other species tested. Therefore, the organism that has both the 16S rRNA gene and lipase gene was identified as P. acnes, while the strain with the lipase gene but not the 16S rRNA gene of P. acnes was characterized as P. avidum. These findings were confirmed by the conventional biochemical tests including lipase activity. Furthermore, out of the seven clinical isolates from acne vulgaris, four were identified as P. acnes and three as P. avidum by the PCR method and biochemical tests. The combination of two PCR, one for the detection of the 16S rRNA and the other of lipase genes was shown to be an easier, faster and more accurate method to identify P. acnes and P. avidum than conventional methods.

Entities:  

Year:  2003        PMID: 16887681     DOI: 10.1016/S1075-9964(03)00061-1

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  7 in total

1.  The distribution of infection with Propionibacterium acnes is equal in patients with cervical and lumbar disc herniation.

Authors:  Naghmeh Javanshir; Firooz Salehpour; Javad Aghazadeh; Farhad Mirzaei; Seyed Ahmad Naseri Alavi
Journal:  Eur Spine J       Date:  2017-07-15       Impact factor: 3.134

Review 2.  Clinical and Biological Features of Cutibacterium (Formerly Propionibacterium) avidum, an Underrecognized Microorganism.

Authors:  Stéphane Corvec
Journal:  Clin Microbiol Rev       Date:  2018-05-30       Impact factor: 26.132

3.  Relationship between annular tear and presence of Propionibacterium acnes in lumbar intervertebral disc.

Authors:  Zezhu Zhou; Zhe Chen; Yuehuan Zheng; Peng Cao; Yu Liang; Xingkai Zhang; Wenjian Wu; Jiaqi Xiao; Shijing Qiu
Journal:  Eur Spine J       Date:  2015-08-19       Impact factor: 3.134

4.  Propionibacterium acnes Infection in Disc Material and Different Antibiotic Susceptibility in Patients With Lumbar Disc Herniation.

Authors:  Firooz Salehpour; Javad Aghazadeh; Farhad Mirzaei; Ehsan Ziaeii; Seyed Ahmad Naseri Alavi
Journal:  Int J Spine Surg       Date:  2019-04-30

5.  Prediction of Antibacterial Peptides against Propionibacterium acnes from the Peptidomes of Achatina fulica Mucus Fractions.

Authors:  Suwapitch Chalongkulasak; Teerasak E-Kobon; Pramote Chumnanpuen
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

6.  Propionibacterium acnes Osteomyelitis after Intraosseous Cannulation in a Child.

Authors:  Keegan A Cole; Samik Banerjee; John A Dipreta
Journal:  Case Rep Orthop       Date:  2019-12-06

7.  Antimicrobial activity of certain natural-based plant oils against the antibiotic-resistant acne bacteria.

Authors:  Ahmed Esmael; Mervat G Hassan; Mahmoud M Amer; Soheir Abdelrahman; Ahmed M Hamed; Hagar A Abd-Raboh; Mohamed F Foda
Journal:  Saudi J Biol Sci       Date:  2019-11-20       Impact factor: 4.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.